A Clinical Safety, In-use Tolerability and Efficacy Study of the Test Product in Heathy Adult Human Subjects With Dry or Sensitive Skin

SAVA Healthcare Limited1 个研究点分布在 1 个国家目标入组 32 人开始时间: 2025年5月15日最近更新: 2025年4月24日

适应症

干预措施

试验速览

阶段: 不适用
状态: 尚未招募
发起方
入组人数: 32
试验地点: 1
主要终点: Change in skin wrinkles

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This exploratory, prospective, open-label, single-centre, safety, efficacy and in-use tolerability study of the test product in healthy adult human subjects with dry or sensitive skin.

详细描述

A total of up to 32 healthy male and non-pregnant | non-lactating female with dry or sensitive skin and an age of 18-55 years will be enrolled to complete the 30 subjects of the study.

The potential subjects will be screened as per the inclusion & exclusion criteria only after obtaining written informed consent from the subjects. Subjects will be pre-screened by the screening department of NovoBliss Research. Subjects will be called telephonically by the recruiting department prior to the enrollment visit. Subjects will be told during screening (prior to enrolment) not to wear any facial make-up on the study visit day. The adult female subjects will be instructed to visit the facility as per the below visits.

Visit 01 (Day 01): Screening, Enrolment, Baseline Evaluation, On Site Product Usage, Post Usage Evaluation Visit 02 (Day 02): Evaluations, Product usage period Visit 03 (Day 15 +2 Days): Evaluations, End of the Study

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Single Group
主要目的: Other
盲法: None

入排标准

年龄范围: 18 Years 至 55 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Age: 18 to 55 years (both inclusive) at the time of consent.
•Sex: Healthy male and non-pregnant/non-lactating females.
•Females of childbearing potential must have a self-reported negative pregnancy test.
•Subject are generally in good health.
•Subject with dry or sensitive skin at a time of screening. (Dermatological Assessment)
•Subjects assessment site must be free of cuts, tattoos, scratches, abrasions, scars, uneven skin tone, sunburn, excessive tan, excessive hair or open wounds.
•Subject is able to remain on stable doses of contraceptive or replacement hormonal therapy, including no therapy, 6 weeks prior to and for the duration of the study.
•If the subject is of childbearing potential, is practicing and agrees to maintain an established method of birth control (IUD, hormonal implant device/injection, regular use of birth control pills or patch, diaphragm, condoms with spermicide or sponge with spermicidal jelly, cream or foam, partner vasectomy or abstinence). Females will be considered as non-childbearing potential if they are surgically sterile, have been post-menopausal for at least 1 year or have had a tubal ligation.
•Subjects are willing to give written informed consent and are willing to come for regular follow up.
•Subjects who commit not to use medicated skincare products other than the test product for the entire duration of the study.
•Subject who have not participated in a similar investigation in the past three months.
•Willing to use test product throughout the study period.

排除标准

•History of any dermatological condition of the skin diseases.
•Subject with present condition of allergic response to any cosmetic product.
•Subject having allergic response to the ink.
•Presence of any broken, chapped, cut, irritated, or scraped skin at the application site.
•Subjects under chronic medication (e.g. aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy etc.) that might influence the outcome of the study.
•Subject having acne of severe incidence (presence of nodules, cysts or numerous pustules) which requires pharmaceutical or cosmeceuticals, herbal treatment.
•Subjects who have applied topical treatment for at least 4 weeks and any systemic treatment for at least 3 months, before they participated in the study.
•History of alcohol or drug addiction.
•Subjects using other marketed products during the study period.
•Any other condition which could warrant exclusion from the study, as per the dermatologist's/investigator's discretion.
•Pregnant or breastfeeding or planning to become pregnant during the study period.
•History of chronic illness which may influence the cutaneous state.
•Subjects participating in other similar cosmetics, devices or therapeutic trials or skincare products within the last four weeks.

研究组 & 干预措施

Creanz Lotion

Experimental

Mode of Usage: Apply sufficient quantity of Creanz Nourishing Body lotion to face and body for smooth and moisturised skin.

Frequency: Twice a Day Route of Administration: Topical

干预措施: Creanz Lotion (Other)